Antiinflammatory effects of H1-antihistamines: Clinical and immunological relevance

Current Pharmaceutical Design

Volumn 14, Issue 27, 2008, Pages 2902-2911

  Vena, G A ^a   Cassano, N ^a   Buquicchio, R ^a   Ventura, M T ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Antihistamine; Cytokines; H1 receptor; Histamine; Inflammation; Mechanism of action; Mediators; Skin

Indexed keywords

ASTEMIZOLE; AZELASTINE; CETIRIZINE; CLEMASTINE; DESLORATADINE; EBASTINE; EPINASTINE; FEXOFENADINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTAMINE H1 RECEPTOR; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR; HISTAMINE H3 RECEPTOR; HISTAMINE H4 RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KETOTIFEN; LEVOCABASTINE; LEVOCETIRIZINE; LORATADINE; MITOGEN ACTIVATED PROTEIN KINASE; MIZOLASTINE; OLOPATADINE; OXATOMIDE; PLACEBO; RANTES; TERFENADINE;

ALLERGIC RHINITIS; ANTIINFLAMMATORY ACTIVITY; ASTHMA; AUTOIMMUNITY; BASOPHIL; CELL SURVIVAL; CELLULAR IMMUNITY; CHEMOTAXIS; CHRONIC INFLAMMATION; CHRONIC URTICARIA; CLINICAL IMMUNOLOGY; CYTOKINE RELEASE; DOWN REGULATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; GENETIC TRANSCRIPTION; GRANULOCYTE FUNCTION; HISTAMINE RELEASE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOTHERAPY; IN VITRO STUDY; KERATINOCYTE; MAST CELL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; POLLEN ALLERGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SKIN DISEASE; T LYMPHOCYTE; URTICARIA;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HISTAMINE H1 ANTAGONISTS; HUMANS; INFLAMMATION MEDIATORS; SKIN TESTS;

EID: 65949092211     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208786369777     Document Type: Review

References (98)

1. MacGlashan D. Histamine: A mediator of inflammation. J. Allergy Clin Immunol 2003; 112: S53-9.
2. Oh C, Suzuki S, Nakashima I, Yamashita K, Nakano K. Histamine synthesis by non-mast cells through mitogen-dependent induction of histidine decarboxylase. Immunology 1988; 65: 143-8.
3. Masini E, Di Bello MG, Raspanti S, Ndisang FJ, Baronti R, Cappugi P, et al. The role of histamine in platelet aggregation by physiological and immunological stimuli. Inflamm Res 1998; 47: 211-20
4. Zwadlo-Klarwasser G, Vogts M, Hamann W, Belke K, Baron J, Schmutzler W. Generation and subcellular distribution of histamine in human blood monocytes and monocyte subsets. Inflamm Res 1998; 47: 434-9.
5. Kubo Y, Nakano K. Regulation of histamine synthesis in mouse CD4+ and CD8+ T lymphocytes. Inflamm Res 1999; 48: 149-53.
6. Shiraishi M, Hirasawa N, Oikawa S, Kobayashi Y, Ohuchi K. Analysis of histamine producing cells at the late phase of allergic inflammation in rats. Immunology 2000; 99: 600-7.
7. Hirasawa N, Torigoe M, Ohgawara R, Murakami A, Ohuchi K. Involvement of MAP kinases in lipopolysaccharide-induced histamine production in RAW 264 cells. Life Sci 2006; 80: 36-42.
8. Tippens AS, Gruetter CA. Detection of histidine decarboxylase mRNA in human vascular smooth muscle and endothelial cells. Inflamm Res 2004; 53: 215-6.
9. Akdis CA, Simons FE. Histamine receptors are hot in immunopharmacology. Eur J Pharmacol 2006; 533: 69-76.
10. Ohtsu H, Watanabe T. New functions of histamine found in histidine decarboxylase gene knockout mice. Biochem Biophys Res Commun 2003; 305: 443-7.
11. Tokita S, Takahashi K, Kotani H. Recent advances in molecular pharmacology of the histamine systems: Physiology and pharmacology of histamine H3 receptor: Roles in feeding regulation and therapeutic potential for metabolic disorders. J Pharmacol Sci 2006; 101: 12-8.
12. Esbenshade TA, Fox GB, Cowart MD. Histamine H3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders. Mol Interv 2006; 6: 77-88.
13. Akdis CA, Blaser K. Histamine in the immune regulation of allergic inflammation. J Allergy Clin Immunol 2003; 112: 15-22.
14. Smit MJ, Hoffmann M, Timmerman H, Leurs R. Molecular properties and signalling pathways of the histamine H1 receptor. Clin Exp Allergy 1999; 29 (Suppl 3): 19-28.
15. Bakker RA, Schoonus SB, Smit MJ, Timmerman H, Leurs R. Histamine H(1)-receptor activation of nuclear factor-kappa B: Roles for G beta gamma- and G alpha(q/11)-subunits in constitutive and agonist-mediated signaling. Mol Pharmacol 2001; 60: 1133-42.
16. Zuberbier T, Bindslev-Jensen C, Canonica W, Grattan CE, Greaves MW, Henz BM, et al. EAACI/GA2LEN/EDF guideline: Management of urticaria. Allergy 2006; 61: 321-31.
17. Leurs R, Church MK, Taglialatela M. H1-antihistamines: Inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy 2002; 32: 489-98.
18. Mota I, Dias Da Silva W. The antianaphylactic and histamine releasing properties of the antihistamines: Their effect on mast cells. Br J Pharmacol 1960; 15: 396-404.
19. Church MK, Gradidge CF. Inhibition of histamine release from human lung in vitro by antihistamines and related drugs. Br J Pharmacol 1980; 69: 663-7.
20. Church MK. Non-H1-receptor effects of antihistamines. Clin Exp Allergy 1999; 29 (Suppl 3): 39-48.
21. Burde R, Dippel E, Seifert R. Receptor-independent G protein activation may account for the stimulatory effects of first-generation H1-receptor antagonists in HL-60 cells, basophils, and mast cells. Biochem Pharmacol 1996; 51: 125-31.
22. Fischer MJ, Paulussen JJ, Horbach DA, Roelofsen EP, van Miltenburg JC, de Mol NJ, et al. Inhibition of mediator release in RBL-2H3 cells by some H1-antagonist derived anti-allergic drugs: Relation to lipophilicity and membrane effects. Inflamm Res 1995; 44: 92-7.
23. Paulussen JJ, Fischer MJ, Zuidam NJ, Miltenburg JC, de Mol NJ, Janssen LH. Influence of the antiallergic drug oxatomide and derivatives on membrane structures: Relation with inhibition of calcium influx in rat basophilic leukemia cells. Biochem Pharmacol 1999; 57: 503-10.
24. Berthon B, Taudou G, Combettes L, Czarléwski W, Carmi-Leroy A, Marchand F, et al. In vitro inhibition, by loratadine and descarboxyethoxyloratadine, of histamine release from human basophils, and of histamine release and intracellular calcium fluxes in rat basophilic leukemia cells (RBL-2H3). Biochem Pharmacol 1994; 47: 789-94.
25. Paulussen JJ, Fischer MJ, Roozendaal RL, van der Heijden VC, van Dijken P, de Mol NJ, et al. Effects of oxatomide and derivatives on high affinity IgE receptor-activated signal transduction pathways in rat basophilic leukemia cells: Role of protein tyrosine hyperphosphorylation and inhibition of extracellular calcium influx. Biochem Pharmacol 1998; 56: 693-701.
26. 2+ influx. Biochem Pharmacol 1998; 55: 1255-62.
27. Xia Q, Zhou WM, Yang S, Zhang SQ, Chen B, Wang DB, et al. Influence of mizolastine on antigen-induced activation of signalling pathways in murine mast cells. Clin Exp Dermatol 2006; 31: 260-5.
28. Hamasaki Y, Shafigeh M, Yamamoto S, Sato R, Zaitu M, Muro E, et al. Inhibition of leukotriene synthesis by azelastine. Ann Allergy Asthma Immunol 1996; 76: 469-75.
29. Hamasaki Y, Kita M, Hayasaki R, Zaitu M, Muro E, Yamamoto S, et al. Inhibition of leukotriene synthesis by terfenadine in vitro. Prostaglandins Leukot Essent Fatty Acids 1998; 58: 265-70
30. Sudo K, Nagai K, Yamada N. Inhibitory effect of mizolastine on 5-lypoxygenase. Jpn Pharmacol Ther 1998; 26: 155-7.
31. Cuss FM. Beyond the histamine receptor: Effect of antihistamines on mast cells. Clin Exp Allergy 1999; 29 (Suppl. 3): 54-9.
32. Okayama Y, Benyon RC, Lowman MA, Church MK. In vitro effects of H1-antihistamines on histamine and PGD2 release from mast cells of human lung, tonsil, and skin. Allergy 1994; 49: 246-53.
33. Triggiani M, Giannattasio G, Balestrieri B, Granata F, Gelb MH, de Paulis A, et al. Differential modulation of mediator release from human basophils and mast cells by mizolastine. Clin Exp Allergy 2004; 34: 241-9.
34. Genovese A, Patella V, De Crescenzo G, De Paulis A, Spadaro G, Marone G. Loratadine and desethoxylcarbonyl-loratadine inhibit the immunological release of mediators from human Fc epsilon RI+ cells. Clin Exp Allergy 1997; 27: 559-67.
35. Kowalski ML, Lewandowska A, Wozniak J, Makowska J, Jankowski A, DuBuske L. Inhibition of nasal polyp mast cell and eosinophil activation by desloratadine. Allergy 2005; 60: 80-5.
36. Campbell A, Michel FB, Bremard-Oury C, Crampette L, Bousquet J. Overview of allergic mechanisms. Ebastine has more than an antihistamine effect. Drugs 1996; 52 (Suppl 1): 15-9.
37. Crampette L, Mainprice B, Bloom M, Bousquet J, Campbell AM. Inhibition of mediator and cytokine release from dispersed nasal polyp cells by terfenadine. Allergy 1996; 51: 346-9.
38. Carayol N, Crampette L, Mainprice B, Ben-Soussen P, Verrecchia M, Bousquet J, et al. Inhibition of mediator and cytokine release from dispersed nasal polyp cells by mizolastine. Allergy 2002; 57: 1067-70.
39. Küsters S, Schuligoi R, Hüttenbrink KB, Rudert J, Wachs A, Szelenyi I, et al. Effects of antihistamines on leukotriene and cytokine release from dispersed nasal polyp cells. Arzneimittelforschung 2002; 52: 97-102.
40. Wang YH, Tache Y, Harris AG, Kreutner W, Daly AF, Wei JY. Desloratadine prevents compound 48/80-induced mast cell degranulation: Visualization using a vital fluorescent dye technique. Allergy 2005; 60: 117-24.
41. Baroody FM, Naclerio RM. Antiallergic effects of H1-receptor antagonists. Allergy 2000; 55: 17-27.
42. Terrien MH, Rahm F, Fellrath JM, Spertini F. Comparison of the effects of terfenadine with fexofenadine on nasal provocation tests with allergen. J Allergy Clin Immunol 1999; 103: 1025-30.
43. Allocco FT, Votypka V, deTineo M, Naclerio RM, Baroody FM. Effects of fexofenadine on the early response to nasal allergen challenge. Ann Allergy Asthma Immunol 2002; 89: 578-84.
44. Bensch GW, Nelson HS, Borish LC. Evaluation of cytokines in nasal secretions after nasal antigen challenge: Lack of influence of antihistamines. Ann Allergy Asthma Immunol 2002; 88: 457-62.
45. Bruno G, Andreozzi P, Magrini L, Santangelo G, Graf U, Angelino A. Serum tryptase in allergic rhinitis: Effect of cetirizine treatment. Int J Immunopathol Pharmacol 2001; 14: 147-52.
46. Hägermark O, Wahlgren CF, Giös I. Inhibitory effect of loratadine and clemastine on histamine release in human skin. Skin Pharmacol 1992; 5: 93-8.
47. Perzanowska M, Malhotra D, Skinner SP, Rihoux JP, Bewley AP, Petersen LJ, et al. The effect of cetirizine and loratadine on codeine-induced histamine release in human skin in vivo assessed by cutaneous microdialysis. Inflamm Res 1996; 45: 486-90.
48. Nielsen PN, Skov PS, Poulsen LK, Schmelz M, Petersen LJ. Cetirizine inhibits skin reactions but not mediator release in immediate and developing late-phase allergic cutaneous reactions. A double-blind, placebo-controlled study. Clin Exp Allergy 2001; 31: 1378-84.
49. Vena GA, Cassano N, Filieri M, Filotico R, D'Argento V, Coviello C. Fexofenadine in chronic idiopathic urticaria: A clinical and immunohistochemical evaluation. Int J Immunopathol Pharmacol 2002; 15: 217-24.
50. 1 antagonist, on platelet activating factor induced bronchoconstriction in asthma. Clin Exp Allergy 1993; 23: 524-7.
51. Redier H, Chanez P, De Vos C, Rifaï N, Clauzel AM, Michel FB, et al. Inhibitory effect of cetirizine on the bronchial eosinophil recruitment induced by allergen inhalation challenge in allergic patients with asthma. J Allergy Clin Immunol 1992; 90: 215-24.
52. Bousquet J, Emonot A, Germouty J, Molina C, Montané F, Perrin-Fayolle M, et al. Double-blind multicenter study of cetirizine in grass-pollen-induced asthma. Ann Allergy 1990; 65: 504-8.
53. 1 antihistamine, on the early and late allergic reactions in a bronchial provocation test with allergen. J Allergy Clin Immunol 1993; 91: 1189-97.
54. Aaronson DW. Evaluation of cetirizine in patients with allergic rhinitis and perennial asthma. Ann Allergy Asthma Immunol 1996; 76: 440-6.
55. Abdelaziz MM, Devalia JL, Khair OA, Bayram H, Prior AJ, Davies RJ. Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of seasonal allergic rhinitics. J Allergy Clin Immunol 1998; 101: 410-20
56. De Vos C. H1-receptor antagonists: Effects on leukocytes, myth or reality? Clin Exp Allergy 1999; 29 (Suppl 3): 60-3.
57. Patou J, De Smedt H, van Cauwenberge P, Bachert C. Pathophysiology of nasal obstruction and meta-analysis of early and late effects of levocetirizine. Clin Exp Allergy 2006; 36: 972-81.
58. Agrawal DK. Anti-inflammatory properties of desloratadine. Clin Exp Allergy 2004; 34: 342-8.
59. Domae M, Sagara H, Sakaue M, Fukuda T, Kamikawa Y. The antiallergic drug oxatomide promotes human eosinophil apoptosis and suppresses IL-5-induced eosinophil survival. J Allergy Clin Immunol 2003; 111: 567-72.
60. Vancheri C, Mastruzzo C, Tomaselli V, Bellistrì G, Pistorio MP, Greco LR, et al. The effect of fexofenadine on expression of intercellular adhesion molecule 1 and induction of apoptosis on peripheral eosinophils. Allergy Asthma Proc 2005; 26: 292-8.
61. Hasala H, Moilanen E, Janka-Junttila M, Giembycz MA, Kankaanranta H. First-generation antihistamines diphenhydramine and chlorpheniramine reverse cytokine-afforded eosinophil survival by enhancing apoptosis. Allergy Asthma Proc 2007; 28: 79-86.
62. Hasala H, Malm-Erjefält M, Erjefält J, Giembycz MA, Zhang X, Moilanen E, et al. Ketotifen induces primary necrosis of human eosinophils. J Ocul Pharmacol Ther 2005; 21: 318-27.
63. Mullol J, Roca-Ferrer J, Alobid I, Pujols L, Valero A, Xaubet A, et al. Effect of desloratadine on epithelial cell granulocyte-macrophage colony-stimulating factor secretion and eosinophil survival. Clin Exp Allergy 2006; 36: 52-8.
64. Cassano N, Raho G, Filieri M, D'Argento V, Amoruso A, Filotico R, et al. Influence of desloratadine on oxidative stress markers in patients with chronic idiopathic urticaria. Int J Dermatol 2006; 45: 394-6.
65. Molet S, Gosset P, Lassalle P, Czarlewski W, Tonnel AB. Inhibitory activity of loratadine and descarboxyethoxyloratadine on histamine-induced activation of endothelial cells. Clin Exp Allergy 1997; 27: 1167-74.
66. Shimizu T, Nishihira J, Watanabe H, Abe R, Ishibashi T, Shimizu H. Cetirizine, an H1-receptor antagonist, suppresses the expression of macrophage migration inhibitory factor: Its potential antiinflammatory action. Clin Exp Allergy 2004; 34: 103-9.
67. Asano K, Kanai K, Suzaki H. Suppressive activity of fexofenadine hydrochloride on thymus- and activation-regulated chemokine production from human peripheral blood leukocytes in response to antigenic stimulation in vitro. Int Arch Allergy Immunol 2004; 133: 267-75.
68. Asano K, Kanai K, Suzaki H. Suppressive activity of fexofenadine hydrochloride on the production of eosinophil chemoattractants from human nasal fibroblasts in vitro. Arzneimittelforschung 2004; 54: 436-43.
69. Ciprandi G, Passalacqua G, Canonica GW. Effects of H1 antihistamines on adhesion molecules: A possible rationale for long-term treatment. Clin Exp Allergy 1999; 29 (Suppl 3): 49-53.
70. Graziano FM, Cook EB, Stahl JL. Antihistamines and epithelial cells. Allergy Asthma Proc 2000; 21: 129-33.
71. Ciprandi G, Tosca MA, Cosentino C, Riccio AM, Passalacqua G, Canonica GW. Effects of fexofenadine and other antihistamines on components of the allergic response: Adhesion molecules. J Allergy Clin Immunol 2003; 112 (Suppl 4): 78-82.
72. Ferreira MB, Santos MC, Pregal AL, Alonso E, Santos AS, Palma-Carlos ML, et al. Effect of specific immunotherapy versus loratadine on serum adhesion molecules. Allerg Immunol (Paris) 2001; 33: 319-22
73. Caproni M, Volpi W, Giomi B, Torchia D, Del Bianco E, Fabbri P. Cellular adhesion molecules in chronic urticaria: Modulation of serum levels occurs during levocetirizine treatment. Br J Dermatol 2006; 155: 1270-4.
74. Boone M, Lespagnard L, Renard N, Song M, Rihoux JP. Adhesion molecule profiles in atopic dermatitis vs. allergic contact dermatitis: pharmacological modulation by cetirizine. J Eur Acad Dermatol Venereol 2000; 14: 263-6.
75. Pestelli E, Floriani I, Fabbri P, Caproni M. Cetirizine modulates adhesion molecule expression in a double-blind controlled study conducted in psoriatic patients. Int J Tissue React 2003; 25: 1-8.
76. Ciprandi G, Cirillo I, Vizzaccaro A. Mizolastine and fexofenadine modulate cytokine pattern after nasal allergen challenge. Allerg Immunol (Paris) 2004; 36: 146-50.
77. Wu RL, Anthes JC, Kreutner W, Harris AG, West RE Jr. Desloratadine inhibits constitutive and histamine-stimulated nuclear factor-kappaB activity consistent with inverse agonism at the histamine H1 receptor. Int Arch Allergy Immunol 2004; 135: 313-8.
78. Yoneda K, Yamamato T, Ueta E, Osaki T. Suppression by azelastine hydrochloride of NF-κB activation involved in generation of cytokines and nitric oxide. Jpn J Pharmacol 1997; 73: 145-53.
79. Ashenager MS, Grgela T, Aragane Y, Kawada A. Inhibition of cytokine-induced expression of T-cell cytokines by antihistamines. J Investig Allergol Clin Immunol 2007; 17: 20-6.
80. Nori M, Iwata S, Munakata Y, Kobayashi H, Kobayashi S, Umezawa Y, et al. Ebastine inhibits T cell migration, production of Th2-type cytokines and proinflammatory cytokines. Clin Exp Allergy 2003; 33: 1544-54.
81. Munakata Y, Umezawa Y, Iwata S, Dong RP, Yoshida S, Ishii T, et al. Specific inhibition of TH2-type cytokine production from human peripheral T cells by terfenadine in vitro. Clin Exp Allergy 1999; 29: 1281-6.
82. Kanai K, Asano K, Watanabe S, Kyo Y, Suzaki H. Epinastine hydrochloride antagonism against interleukin-4-mediated T cell cytokine imbalance in vitro. Int Arch Allergy Immunol 2006; 140: 43-52.
83. Blümchen K, Gerhold K, Thorade I, Seib C, Wahn U, Hamelmann E. Oral administration of desloratadine prior to sensitization prevents allergen-induced airway inflammation and hyper-reactivity in mice. Clin Exp Allergy 2004; 34: 1124-30.
84. Ciprandi G, Cirillo I, Vizzaccaro A, Civardi E, Barberi S, Allen M, et al. Desloratadine and levocetirizine improve nasal symptoms, airflow, and allergic inflammation in patients with perennial allergic rhinitis: A pilot study. Int Immunopharmacol 2005; 5: 1800-8.
85. Tworek D, Bocheńska-Marciniak M, Kupczyk M, Górski P, Kuna P. The effect of 4 weeks treatment with desloratadine (5mg daily) on levels of interleukin (IL)-4, IL-10, IL-18 and TGF beta in patients suffering from seasonal allergic rhinitis. Pulm Pharmacol Ther 2007; 20: 244-9.
86. Schroeder JT, Schleimer RP, Lichtenstein LM, Kreutner W. Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine. Clin Exp Allergy 2001; 31: 1369-77.
87. 1-antagonist decarboethoxy-loratadine and dexamethasone by human mast and basophilic cell lines. Exp Dermatol 1995; 4: 272-6.
88. Lippert U, Moller A, Welker P, Artuc M, Henz BM. Inhibition of cytokine secretion from human leukemic mast cells and basophils by H1- and H2-receptor antagonists. Exp Dermatol 2000; 9: 118-24.
89. Kempuraj D, Huang M, Kandere-Grzybowska K, Basu S, Boucher W, Letourneau R, et al. Azelastine inhibits secretion of IL-6, TNF-alpha and IL-8 as well as NF-kappaB activation and intracellular calcium ion levels in normal human mast cells. Int Arch Allergy Immunol 2003; 132: 231-9.
90. Giustizieri ML, Albanesi C, Fluhr J, Gisondi P, Norgauer J, Girolomoni G. H1 histamine receptor mediates inflammatory responses in human keratinocytes. J Allergy Clin Immunol 2004; 114: 1176-82.
91. 2+-dependent protein kinase C, Raf/ MEK/ERK and IKK/I kappa B/NF-kappa B signal cascades. Biochem Pharmacol 2005; 69: 433-49.
92. Traidl-Hoffmann C, Münster I, Ring J, Behrendt H. Impact of desloratadine and loratadine on the crosstalk between human keratinocytes and leukocytes: Implications for anti-inflammatory activity of antihistamines. Int Arch Allergy Immunol 2006; 140: 315-20.
93. Warner JO; ETAC Study Group. Early Treatment of the Atopic Child. A double-blinded, randomized, placebo-controlled trial of cetirizine in preventing the onset of asthma in children with atopic dermatitis: 18 months' treatment and 18 months' posttreatment follow-up. J Allergy Clin Immunol 2001; 108: 929-37.
94. Simons FE, Silver NA, Gu X, Simons KJ. Skin concentrations of H1-receptor antagonists. J Allergy Clin Immunol 2001; 107: 526-30.
95. Simons FE, Silver NA, Gu X, Simons KJ. Clinical pharmacology of H1-antihistamines in the skin. J Allergy Clin Immunol 2002; 110: 777-83.
96. Alcaraz MJ, Guillen MI, Ferrandiz ML, Megias J, Motterlini R. Carbon monoxide-releasing molecules: A pharmacological expedient to counteract inflammation. Curr Pharm Des 2008; 14(5): 465-72.
97. De Simone G, Di Fiore A, Supuran CT. Are carbonic anhydrase inhibitors suitable for obtaining antiobesity drugs? Curr Pharm Des 2008; 14(7): 655-60.
98. Dogne JM, Thiry A, Supuran CT. Carbonic anhydrase inhibition: Insight into non-COX-2 pharmacological effect of some coxibs. Curr Pharm Des 2008; 14(7): 679-84.